You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

immunogenic cell death

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Cancer, Cervical Cancer, Triple Negative Breast Cancer Trial in Sutton (ASTX660, Pembrolizumab)

Recruiting
  • Advanced Cancer
  • +2 more
  • Sutton, United Kingdom
    Royal Marden NHS Foundation Trust
May 25, 2022

Mitomycin C Activity in Bladder Cancer

Unknown status
  • Bladder Cancer
  • This is an observational study that does not concern a direct intervention on patients and control subjects and does not interfere with the clinical management of patients.
  • Rozzano, Milan, Italy
    Humanitas reseach hospital (ICH)
Jul 4, 2020

Cancer, Treatment-Related, Tumor of Breast, Systemic Inflammatory Response Trial in Roma (cryoablation)

Completed
  • Cancer, Treatment-Related
  • +3 more
  • cryoablation
  • Roma, Italy
    Sapienza University of Rome
Feb 13, 2023

Non Small Cell Lung Cancer Trial in Leuven, Maastricht (Blood withdrawal)

Completed
  • Non Small Cell Lung Cancer
  • Blood withdrawal
  • Leuven, Belgium
  • +1 more
Aug 20, 2019

NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Wuhan, Hubei, China
    Qian Chu
Aug 18, 2023

NSCLC (NSCLC) Trial in Shanghai (Tumor treating fields(EFE-P100), Docetaxel injection)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • Tumor treating fields（EFE-P100）
  • Docetaxel injection
  • Shanghai, China
    Shanghai Pulmonary Hospital
Dec 21, 2022

Anti-Programmed Cell Death Protein 1 Immunotherapy in Head and

Recruiting
  • Head and Neck Cancer
  • Strasbourg, France
    Institut de cancérologie Strasbourg Europe
Apr 14, 2022

NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +4 more
  • MK-2870
  • +2 more
  • (no location specified)
Sep 15, 2023

Cutaneous T-Cell Lymphoma, Graft Vs Host Disease, Graft Rejection Trial in Besançon (Samples collection)

Recruiting
  • Cutaneous T-Cell Lymphoma
  • +2 more
  • Samples collection
  • Besançon, France
    Centre Hospitalier Universitaire de Besançon
May 31, 2022

Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell

Recruiting
  • Primary Immune Deficiency
    • Bethesda, Maryland
    • +6 more
    Feb 2, 2023

    Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization, Tyrosine Kinase Inhibitor Trial in Chengdu (lenvatinib

    Enrolling by invitation
    • Hepatocellular Carcinoma Non-resectable
    • +3 more
    • lenvatinib + sindilimab/carrelizumab
    • TACE
    • Chengdu, Sichuan, China
      West China Hospital of Sichuan University
    May 23, 2022

    Metastatic Nonsmall Cell Lung Cancer, Non Small Cell Lung Cancer Trial in Philadelphia (Stereotactic Body Radiotherapy)

    Active, not recruiting
    • Metastatic Nonsmall Cell Lung Cancer
    • Non Small Cell Lung Cancer
    • Stereotactic Body Radiotherapy
    • Philadelphia, Pennsylvania
      Philadelphia CyberKnife
    Mar 15, 2022

    Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation Trial in Peking (Pembrolizumab, pemetrexed,

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • +2 more
    • Peking, China
      Peking Union Medical College Hospital
    Nov 16, 2023

    PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC

    Recruiting
    • Non-small Cell Lung Cancer
    • Monza, Italy
      ASST-Monza Ospedale San Gerardo
    Jun 9, 2022

    Cardiac Arrhythmias in Subjects Treated With BTK Inhibitors

    Recruiting
    • Chronic Lymphocytic Leukemia (CLL)
    • +5 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Feb 16, 2023

      Esophageal Squamous Cell Carcinoma Trial (Paclitaxel, Irinotecan, Pembrolizumab)

      Recruiting
      • Esophageal Squamous Cell Carcinoma
      • Chuo-ku, Tokyo, Japan
        National Cancer Center Hospital ( Site 3700)
      Jan 31, 2023

      Acute Lymphoblastic Leukemia in Pediatric Trial in Sohag (flow cytometric immunophynotyping)

      Not yet recruiting
      • Acute Lymphoblastic Leukemia in Pediatric
      • flow cytometric immunophynotyping
      • Sohag, Egypt
        Sohag University Hospital
      Jun 19, 2022

      Deeply Phenotype Major Organs in Sickle Cell Disease After

      Enrolling by invitation
      • Mortality in Sickle Cell
      • +4 more
        • Bethesda, Maryland
          National Institutes of Health Clinical Center
        Jul 13, 2022

        Tumor-Infiltrating Lymphocytes and Programmed Cell Death -

        Recruiting
        • Breast Cancer
        • +2 more
        • Observational Study
        • Lucknow, Uttar Pradesh, India
          Sanjay Gandhi Postgraduate Institute of Medical Sciences
        Feb 11, 2022

        Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma Trial in Changchun (Rituximab,

        Recruiting
        • Peripheral T-Cell Lymphoma, Not Otherwise Specified
        • Angioimmunoblastic T-cell Lymphoma
        • Changchun, Jilin, China
          The First Bethune Hospital of Jilin University
        Apr 7, 2023

        NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)

        Active, not recruiting
        Has Results
        • Non-small Cell Lung Cancer
        • pembrolizumab
        • +3 more
        • (no location specified)
        Aug 18, 2022

        NSCLC Trial in Marietta, Taichung City, Tainan (Sacituzumab Govitecan, Pembrolizumab)

        Recruiting
        • Carcinoma, Non-Small-Cell Lung
        • Sacituzumab Govitecan
        • Pembrolizumab
        • Marietta, Georgia
        • +2 more
        Jan 27, 2023

        Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy Trial in Guangzhou (Toripalimab,

        Not yet recruiting
        • Muscle-Invasive Bladder Carcinoma
        • +2 more
        • Guangzhou, Guangdong, China
          Cancer Center, Sun Yat-sen University
        Aug 3, 2023

        NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)

        Active, not recruiting
        Has Results
        • Non-small Cell Lung Cancer
        • pembrolizumab
        • +3 more
        • (no location specified)
        Aug 18, 2022

        Pilon Fracture Trial in Columbia (N-acetylcysteine, Saline)

        Recruiting
        • Pilon Fracture
        • Columbia, Missouri
          University of Missouri Health System
        Nov 2, 2022